Fundamental Analysis Stories

<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#800000;color: #F0FFF0;font-size:0.9em;;'>MOV</div>
  over three months ago at Macroaxis 
By Vlad Skutelnik
Movado Cash and Equivalents Turnover is fairly stable at the moment as compared to the past year. Movado reported Cash and Equivalents Turnover of 3.73 in 2019. Cash Flow Per Share is likely to climb to 1.72 in 2020, whereas Average Assets are likely to drop slightly above 786.8 M in 2020. Movado Group is scheduled to announce its earnings today. The next earnings report is expected on the 25th of March 2021. As some conservatives are trying to avoid consumer cyclical space, we'll focus on Movado Group a little further and explain its current market possibilities. We will look into reasons why it is still very possible for the company to generate above-average returns. Will sophisticated investors continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#169D0B;color: #FFFFF0;font-size:1.1em;;'>KI</div>
  over three months ago at Macroaxis 
By Achuva Shats
Korn Ferry Accounts Payable Turnover is fairly stable at the moment as compared to the past year. Korn Ferry reported Accounts Payable Turnover of 46.49 in 2019. Cash and Equivalents Turnover is likely to rise to 3.04 in 2020, whereas Average Assets are likely to drop slightly above 2.2 B in 2020. Korn Ferry is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 23rd of November 2020. While some generation-Y investors are indifferent towards industrials space, it makes sense to break down Korn Ferry using its fundamentals . We will evaluate why we are still confident in anticipation of a recovery. We currently estimate Korn Ferry as overvalued. The real value is approaching 35.89 per share.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#483D8B;color: #f2f2f2;font-size:0.9em;;'>IBI</div>
  over three months ago at Macroaxis 
By Raphi Shpitalnik
IBio Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 100.39 Million. Working Capital is expected to rise to about 61 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (12.7 M). One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will outline IBio. We currently estimate IBio as undervalued. The real value is approaching 2.08 per share.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#169D0B;color: #FFFFF0;font-size:1.1em;;'>OM</div>
  over three months ago at Macroaxis 
By Achuva Shats
Odyssey Marine Cash and Equivalents Turnover is fairly stable at the moment as compared to the past year. Odyssey Marine reported Cash and Equivalents Turnover of 2.06 in 2019. Revenue to Assets is likely to rise to 0.65 in 2020, whereas Net Income Per Employee is likely to drop (804.6 K) in 2020. In spite of fairly strong basic indicators, Odyssey Marine is not utilizing all of its potentials. The current stock price disturbance, may contribute to a short-term swings for the investors. We currently estimate Odyssey Marine as overvalued. The real value is approaching 4.41 per share.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#483D8B;color: #f2f2f2;font-size:1.1em;;'>AI</div>
  over three months ago at Macroaxis 
By Vlad Skutelnik
Aim Immunotech Market Capitalization is relatively stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 4.61 Million. Tangible Asset Value is expected to hike to about 23.8 M this year, although the value of Earnings before Tax will most likely fall to (10.3 M). If you are looking to grow your portfolio over time, you may want to summarize all of the essential forward indicators of your selected equities before buying their shares. In this article, we will summarize Aim Immunotech. We will analyze why Aim Immunotech investors may still consider a stake in the business. Aim Immunotech current probability of bankruptcy is over 66%. Are the company stakeholders still optimistic?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0000;color: #F8F8FF;font-size:1.1em;;'>TP</div>
  over three months ago at Macroaxis 
By Raphi Shpitalnik
Titan Pharmaceuticals Market Capitalization is very stable at the moment as compared to the past year. Titan Pharmaceuticals reported last year Market Capitalization of 102.42 Million. As of 13th of November 2020, Tangible Asset Value is likely to grow to about 15.7 M, while Free Cash Flow is likely to drop (7.4 M). There are many examples of share prices declining after an abrupt shift in one of the basic indicators. Let's recap some of Titan Pharmaceuticals' important ratios. We will evaluate why recent Titan Pharmaceuticals price moves suggest a bounce in December. Will insiders continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#1A69FC;color: #ffffff;font-size:1.1em;;'>RB</div>
  over three months ago at Macroaxis 
By Achuva Shats
REGENERX BIOPHARMACEUTICA is scheduled to announce its earnings today. As many risky investors are excited about healthcare space, it is only fair to break down REGENERX BIOPHARMACEUTICALS based on its current volatility. We will evaluate why recent REGENERX BIOPHARMACEUTICA price moves suggest a bounce in December. This firm current probability of distress is over 95%. Are REGENERX BIOPHARMACEUTICA investors still optimistic?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0000;color: #F8F8FF;font-size:1.1em;;'>DR</div>
  over three months ago at Macroaxis 
By Raphi Shpitalnik
If you have been following Draftkings you may be considering purchasing. Let's check if sound basic indicators will continue to push the price to surge for Draftkings' shareholders. Draftkings odds of financial distress is under 41 percent. Will Draftkings shareholders continue to acquire in December?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#483D8B;color: #f2f2f2;font-size:1.1em;;'>NT</div>
  over three months ago at Macroaxis 
By Gabriel Shpitalnik
Northern Technologies Free Cash Flow is projected to increase significantly based on the last few years of reporting. The past year's Free Cash Flow was at 5.19 Million. The current year Current Ratio is expected to grow to 5.02, whereas Average Assets are forecasted to decline to about 68 M. Despite somewhat strong technical indicators, Northern Technologies is not utilizing all of its potentials. The newest stock price disturbance, may contribute to a short-term swings for the investors. Northern Technologies Internati probability of bankruptcy is over 52 percent. Will investors continue to be optimistic, or should we expect a sell-off in December?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#006400;color: #F5FFFA;font-size:1.1em;;'>NM</div>
  over three months ago at Macroaxis 
By Ellen Johnson
Nova Measuring Invested Capital is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital was reported at 172.85 Million. The current Invested Capital Average is estimated to increase to about 136 M, while Average Assets are projected to decrease to roughly 298.2 M. Nova Measuring Instr is scheduled to announce its earnings today. The next earnings report is expected on the 11th of February 2021. Many investors are getting excited about technology space, let's analyze if Nova Measuring Instruments fundamentals are strong enough to attract traders. We will evaluate why recent Nova Measuring price moves suggest a bounce in December. We currently estimate Nova Measuring as overvalued. The real value is approaching 53.97 per share.